The Real‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
- 14 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), 169-173
- https://doi.org/10.1016/j.clml.2021.09.010
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaBlood, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2018
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLBlood, 2018
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyBlood, 2018
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceBlood, 2018
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patientsHaematologica, 2016
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studyThe Lancet Oncology, 2016
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia GroupHaematologica, 2016
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014